C4XD vs. OBD, HEMO, AREC, OBI, ONC, OPTI, SBTX, TRX, SAR, and NSCI
Should you be buying C4X Discovery stock or one of its competitors? The main competitors of C4X Discovery include Oxford BioDynamics (OBD), Hemogenyx Pharmaceuticals (HEMO), Arecor Therapeutics (AREC), Ondine Biomedical (OBI), Oncimmune (ONC), OptiBiotix Health (OPTI), SkinBioTherapeutics (SBTX), Tissue Regenix Group (TRX), Sareum (SAR), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.
C4X Discovery (LON:C4XD) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.
In the previous week, Oxford BioDynamics had 2 more articles in the media than C4X Discovery. MarketBeat recorded 3 mentions for Oxford BioDynamics and 1 mentions for C4X Discovery. C4X Discovery's average media sentiment score of 0.67 beat Oxford BioDynamics' score of 0.13 indicating that C4X Discovery is being referred to more favorably in the media.
C4X Discovery has a net margin of 42.81% compared to Oxford BioDynamics' net margin of 0.00%. C4X Discovery's return on equity of 55.38% beat Oxford BioDynamics' return on equity.
52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 36.5% of Oxford BioDynamics shares are held by institutional investors. 27.1% of C4X Discovery shares are held by company insiders. Comparatively, 15.5% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
C4X Discovery has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Oxford BioDynamics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.
C4X Discovery has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.
Oxford BioDynamics received 16 more outperform votes than C4X Discovery when rated by MarketBeat users. However, 77.88% of users gave C4X Discovery an outperform vote while only 61.54% of users gave Oxford BioDynamics an outperform vote.
Summary
C4X Discovery beats Oxford BioDynamics on 12 of the 16 factors compared between the two stocks.
Get C4X Discovery News Delivered to You Automatically
Sign up to receive the latest news and ratings for C4XD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding C4XD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
C4X Discovery Competitors List
Related Companies and Tools